新型凝血试验检测抗凝抵抗并与需体外膜氧合儿科患者的血栓事件相关
本研究为单中心回顾性实验室样本分析与病历回顾,纳入15例抗凝儿科患者的41份枸橼酸化冻存血浆标本(21份用比伐卢定、20份用普通肝素),其中13例在体外膜氧合、1例次大面积肺栓塞、1例左心室辅助装置。研究评估一种快速(<10分钟)、微量(<50微升)凝血时间终点试验能否检测并定量比伐卢定与普通肝素的抗凝效果,并为每份样本推导凝血时间评分(CTS)。CTS检测病理性血栓事件的敏感性为100%、特异性为82%,而凝血酶原时间敏感性25%/特异性76%、活化部分凝血活酶时间敏感性0%/特异性0%。CTS还检测出临床判定为普通肝素抵抗、需改用比伐卢定患者的抗凝不足。作者认为CTS似乎是有价值的凝血状态指标,可能通过快速识别病理性血栓事件高危患者来降低抗凝相关并发症风险。
要点
- 在15例抗凝儿科患者的41份血浆标本中,CTS检测病理性血栓事件的敏感性为100%、特异性为82%。
- 凝血酶原时间检测病理性血栓事件的敏感性为25%、特异性为76%;活化部分凝血活酶时间为敏感性0%、特异性0%。
- CTS检测出临床判定为普通肝素抵抗、需改用比伐卢定患者的抗凝不足。
- 该试验快速(<10分钟)、微量(<50微升),以功能性凝血时间终点定量比伐卢定与普通肝素的抗凝效果。
- 作者认为CTS似乎是有价值的凝血状态指标,可能通过快速识别病理性血栓事件高危患者来降低抗凝相关并发症风险。
适用人群与场景
- 抗凝治疗的儿科重症患者:15例中13例在体外膜氧合、1例次大面积肺栓塞、1例左心室辅助装置。
- 标本来源为105张床位的儿科与心脏ICU(提供体外膜氧合)。
研究设计与关键结果
- 设计:单中心回顾性实验室样本分析与病历回顾;41份枸橼酸化冻存血浆标本(21份比伐卢定、20份普通肝素)来自15例抗凝儿科患者。
- CTS检测病理性血栓事件:敏感性100%、特异性82%;凝血酶原时间敏感性25%/特异性76%;活化部分凝血活酶时间敏感性0%/特异性0%。
- CTS检测出临床判定为普通肝素抵抗、需改用比伐卢定患者的抗凝不足。
- 试验特性:快速(<10分钟)、微量(<50微升),以功能性凝血时间终点定量抗凝效果。
证据类型、等级与局限
- 证据类型:单中心回顾性实验室样本分析与病历回顾。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为CTS似乎是有价值的凝血状态指标,可用于普通肝素或比伐卢定治疗患者。
- 作者认为因剂量不足或抗凝抵抗导致结果超出治疗范围似乎与血栓形成相关。
- 作者认为CTS检测可能通过快速识别病理性血栓事件高危患者来降低抗凝相关并发症风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Bivalirudin, an IV direct thrombin inhibitor, and unfractionated heparin (UFH) are frequently used anticoagulants in the pediatric critical care setting. An accurate, specific, point-of-care test to quantify and detect anticoagulation resistance is not currently available. This study evaluates the ability of a rapid (< 10 min), micro-volume (< 50 uL) coagulation test to detect and quantify the anticoagulation effect of bivalirudin and UFH using a functional, clot time endpoint in pediatric critical care patients.
DESIGN: Single-site retrospective laboratory sample analysis and chart review.
SETTING: A 105-bed pediatric and cardiac ICUs delivering extracorporeal membrane oxygenation.
SUBJECTS: Forty-one citrated, frozen, biobanked plasma specimens comprising 21 with bivalirudin and 20 with UFH from 15 anticoagulated pediatric patients were analyzed. Thirteen patients were on extracorporeal membrane oxygenation, one had a submassive pulmonary embolism, and one was on a left ventricular assist device.
INTERVENTIONS: None.
MEASUREMENT AND MAIN RESULTS: A Clotting Time Score (CTS) was derived on each sample. The CTS detected patients that had developed a pathologic clotting event with 100% sensitivity and 82% specificity compared with prothrombin time with 25% sensitivity/76% specificity and activated partial thromboplastin time with 0% sensitivity/0% specificity. Additionally, the CTS detected subtherapeutic anticoagulation in response to UFH in patients that were clinically determined to be UFH resistant requiring alternative anticoagulation with bivalirudin.
CONCLUSIONS: The CTS appears to be a clinically valuable indicator of coagulation status in patients treated with either UFH or bivalirudin. Results outside of the therapeutic range due to inadequate dosing or anticoagulation resistance appeared to be associated with clot formation. CTS testing may reduce the risk of anticoagulation-related complications via the rapid identification of patients at high risk for pathologic thrombotic events.
参考来源
- Frydman GH, Berger BM, Kostousov V, et al. Novel Coagulation Test Detects Anticoagulation Resistance and Is Associated With Thrombotic Events in Pediatric Patients Requiring Extracorporeal Membrane Oxygenation. Crit Care Explor. 2022. PMID: 36311559. doi:10.1097/CCE.0000000000000776
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。